Status:
TERMINATED
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
Lead Sponsor:
Bristol-Myers Squibb
Collaborating Sponsors:
Mayo Clinic
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate oral doses of BMS-754807 in combination with letrozole or BMS-754807 alone are safe and efficacious in locally advanced or metastatic hormone receptor positive...
Eligibility Criteria
Inclusion
- For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
- Postmenopausal women with hormone receptor-positive and HER-2 negative breast cancer
- Disease progression following non-steroidal aromatase inhibitor treatment
Exclusion
- Known symptomatic brain metastasis
- Medical condition requiring chronic steroids
- History of Type 1 or 2 Diabetes
- Uncontrolled or significant cardiovascular (CV) disease
- Concomitant second malignancies
Key Trial Info
Start Date :
December 31 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 30 2014
Estimated Enrollment :
77 Patients enrolled
Trial Details
Trial ID
NCT01225172
Start Date
December 31 2010
End Date
November 30 2014
Last Update
August 11 2020
Active Locations (21)
Enter a location and click search to find clinical trials sorted by distance.
1
Univ Of Al At Birmingham
Birmingham, Alabama, United States, 35294
2
Mayo Clinic Arizona
Scottsdale, Arizona, United States, 85259
3
Sharp Clinical Oncology Research
San Diego, California, United States, 92123
4
Mayo Clinic
Jacksonville, Florida, United States, 32224